(Total Views: 470)
Posted On: 03/30/2021 1:21:14 PM
Post# of 148899
No I didn’t sell and it’s not only a problem if I sold. First, a relative short term change in SP can have significant impact on the long term SP. Second, speed to market can have an even bigger impact on SP.
A month ago we were trading between $4 and $5, this information would have pushed the SP north of that. Now our baseline is $2 ish - let’s just see if this information pushes us well past $5.
The bigger issue is that if we see mismanagement with the CD12 trial design, management and data why would we expect any change with CD16, or CD 17, or cancer or NASH?
A month ago we were trading between $4 and $5, this information would have pushed the SP north of that. Now our baseline is $2 ish - let’s just see if this information pushes us well past $5.
The bigger issue is that if we see mismanagement with the CD12 trial design, management and data why would we expect any change with CD16, or CD 17, or cancer or NASH?
(2)
(0)Scroll down for more posts ▼
